Clinical Trial: A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients

U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07408219) titled 'A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients' on Feb. 06.

Brief Summary: This is a United States (US) based, prospective, non-interventional, provider-referral study to evaluate the real-world effectiveness and patient-centered outcomes of remibrutinib in chronic spontaneous urticaria (CSU) patients using validated patient reported outcome (PRO) tools.

Study Start Date: Jan. 14

Study Type: OBSERVATIONAL

Condition: Chronic Spontaneous Urticaria

Recruitment Status: RECRUITING

Sponsor: Novartis Pharmaceuticals

Disclaimer: Curated by HT Syndication....